1AI 0.00% 1.0¢ algorae pharmaceuticals limited

Final, Group 3, Phase II Trials, page-2

  1. 95 Posts.
    I have accumulated over the past 5 years to build a substantial holding over this period. With a major milestone now so close I certainly won’t be parting with a single share.

    I can’t understand how the market cap of this company has remained at $50M as the phase 2 trial progresses in line with plan and the phase 1 patients continue to improve several years after implant. IIL for example who are currently in phase 2 trials with results expected at the same time as NTCELL has increase to a market cap of $300M.

    Despite the lack of media attention when phase 2 results are released the results will speak for themselves where long term holders will be rewarded. 2017 is a make or break year for LCT, we'll either be at 2 cents or 50 cents by the end of the year….
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $16.87M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $1.3K 130K

Buyers (Bids)

No. Vol. Price($)
7 4791986 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 1107268 8
View Market Depth
Last trade - 10.00am 21/06/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.